Table 4.
Survival among study groups according to Kaplan–Meier estimates.
| Characteristics | Study groups | ||
|---|---|---|---|
| CE-CT (n = 144) | FDG-PET/CT (n = 83) | Combined (n = 73) | |
| Total number of deathsa | 123 (85.4) | 45 (54.2) | 47 (64.4) |
| Survival probabilitiesb (%) | |||
| 2-year survival | 63.9 (55.4–71.1) | 69.3 (58.0–78.1) | 87.7 (77.6–93.4) |
| 5-year survival | 15.8 (9.8–23) | 41.9 (29.0–54.2) | 43.3 (30.6–55.4) |
| 10-year survival | – | 20.9 (7.4–39.1) | 23.0 (12.3–35.7) |
| Survival timeb (months) | |||
| All patients | 30.0 (25.4–36.0) | 44.3 (29.7–80.2) | 54.0 (44.3–80.1) |
| Triple-negative patientsc | 12.4 (8.4–31.6) | 12.2 (4.2–20.5) | 44.3 (7.4–∞) |
| Patients with bone-only metastasis | 33.9 (17.5–52.9) | 82.6 (15.5–∞) | 58.0 (31.2–80.1) |
| Patients with oligometastatic cancer | 40.3 (29.1–54.4) | 94.0 (46.5–∞) | 87.1 (44.3–∞) |
| Patients received experimental treatments | 31.8 (12.0–48) | – | 85.0 (33.9–90.9) |
CE-CT Contrast-enhanced computed tomography, FDG-PET/CT Fluorodeoxyglucose positron emission tomography with integrated computed tomography.
aData shown as frequency (%).
bData shown as median (95% confidence interval).
cNegative for oestrogen receptors, progesterone receptors and excess HER2 protein.